LiquidCell Dx announced development of a liquid-biopsy platform, LiquidTME, designed to predict response to immune checkpoint inhibitors by profiling tumor microenvironment ecosystems. The startup is using cell-free DNA methylation profiling linked to spatially defined tumor ecotypes. The company said LiquidTME’s methodology was published in Nature based on work assembling bulk and single-cell/spatial transcriptomics datasets across 132 primary human tumors spanning 10 cancer types. Using machine learning, the team identified nine multicellular spatial communities and associated these ecotypes with clinical outcomes and therapy response signals. LiquidCell Dx added it is building an evidence base for commercialization and is in discussions with regulators on a commercialization pathway. The stated strategy addresses a practical bottleneck: translating complex TME measurements into actionable, noninvasive biomarkers. For companion diagnostic and precision oncology ecosystems, the key event is a bridge from discovery to regulatory-intent commercialization planning tied to ICI response.